{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:09:11Z","timestamp":1793506151725,"version":"4.5.0"},"reference-count":160,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Transplant."],"abstract":"<jats:p>Type 1 diabetes (T1D) is characterized by the autoimmune destruction of insulin-producing \u03b2 cells within pancreatic islets, the specialized endocrine cell clusters of the pancreas. Islet transplantation has emerged as a \u03b2 cell replacement therapy, involving the infusion of cadaveric islets into a patient's liver through the portal vein. This procedure offers individuals with T1D the potential to restore glucose control, reducing or even eliminating the need for exogenous insulin therapy. However, it does not address the underlying autoimmune condition responsible for T1D. The need for systemic immunosuppression remains the primary barrier to making islet transplantation a more widespread therapy for patients with T1D. Here, we review recent progress in addressing the key limitations of islet transplantation as a viable treatment for T1D. Concerns over systemic immunosuppression arise from its potential to cause severe side effects, including opportunistic infections, malignancies, and toxicity to transplanted islets. Recognizing the risks, the Edmonton protocol (2000) marked a shift away from glucocorticoids to prevent \u03b2 cell damage specifically. This transition led to the development of combination immunosuppressive therapies and the emergence of less toxic immunosuppressive and anti-inflammatory drugs. More recent advances in islet transplantation derive from islet encapsulation devices, biomaterial platforms releasing immunomodulatory compounds or surface-modified with immune regulating ligands, islet engineering and co-transplantation with accessory cells. While most of the highlighted studies in this review remain at the preclinical stage using mouse and non-human primate models, they hold significant potential for clinical translation if a transdisciplinary research approach is prioritized.<\/jats:p>","DOI":"10.3389\/frtra.2025.1514956","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T07:46:57Z","timestamp":1742456817000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["From Edmonton to Lantidra and beyond: immunoengineering islet transplantation to cure type 1 diabetes"],"prefix":"10.3389","volume":"4","author":[{"given":"El Hadji Arona","family":"Mbaye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan A.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline A.","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"145","DOI":"10.36469\/001c.124604","article-title":"We are on the verge of breakthrough cures for type 1 diabetes, but who are the 2 million Americans who have it?","volume":"11","author":"Smith","year":"2024","journal-title":"J Health Econ Outcomes Res"},{"key":"B2","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S0140-6736(06)68341-4","article-title":"Type 1 diabetes","volume":"367","author":"Daneman","year":"2006","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"100466","DOI":"10.1016\/j.xcrm.2021.100466","article-title":"Insulin expression and C-peptide in type 1 diabetes subjects implanted with stem cell-derived pancreatic endoderm cells in an encapsulation device","volume":"2","author":"Shapiro","year":"2021","journal-title":"Cell Rep Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1391504","DOI":"10.3389\/fimmu.2024.1391504","article-title":"Pancreatic islet transplantation: current advances and challenges","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"10507","DOI":"10.3389\/ti.2022.10507","article-title":"A worldwide survey of activities and practices in clinical islet of Langerhans transplantation","volume":"35","author":"Berney","year":"2022","journal-title":"Transpl Int"},{"key":"B6","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/nrendo.2016.178","article-title":"Clinical pancreatic islet transplantation","volume":"13","author":"Shapiro","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S0140-6736(97)08496-1","article-title":"Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens","volume":"351","author":"Dantal","year":"1998","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.3390\/cells12202423","article-title":"The current status of allogenic islet cell transplantation","volume":"12","author":"Czarnecka","year":"2023","journal-title":"Cells"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1097\/TP.0b013e31818a7f45","article-title":"Improved long-term health related quality of life after islet transplantation","volume":"86","author":"Tharavanij","year":"2008","journal-title":"Transplantation"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.2337\/dc17-1779","article-title":"Improved health-related quality of life in a phase 3 islet transplantation trial in type 1 diabetes complicated by severe hypoglycemia","volume":"41","author":"Foster","year":"2018","journal-title":"Diabetes Care"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1097\/TP.0000000000002242","article-title":"Contemporary strategies and barriers to transplantation tolerance","volume":"102","author":"Ezekian","year":"2018","journal-title":"Transplantation"},{"key":"B12","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJM200007273430401","article-title":"Islet transplantation in seven patients with type 1 diabetes Mellitus using a glucocorticoid-free immunosuppressive regimen","volume":"343","author":"Shapiro","year":"2000","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.molmet.2019.12.012","article-title":"Glucocorticoid induces human beta cell dysfunction by involving riborepressor GAS5 LincRNA","volume":"32","author":"Esguerra","year":"2019","journal-title":"Mol Metab"},{"key":"B14","article-title":"Daclizumab withdrawn from NHS after safety concerns | MS Society","year":"2018"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1056\/NEJMoa061267","article-title":"International trial of the Edmonton protocol for islet transplantation","volume":"355","author":"Shapiro","year":"2006","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1097\/00007890-199311000-00029","article-title":"Blood distribution of rapamycin","volume":"56","author":"Yatscoff","year":"1993","journal-title":"Transplantation"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1111\/ajt.13309","article-title":"Pharmacokinetics and toxicity of tacrolimus early after heart and lung transplantation","volume":"15","author":"Sikma","year":"2015","journal-title":"Am J Transplant"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1097\/01.TP.0000081043.23751.81","article-title":"Elevated portal vein drug levels of sirolimus and tacrolimus in islet transplant recipients: local immunosuppression or islet toxicity?","volume":"76","author":"Desai","year":"2003","journal-title":"Transplantation"},{"key":"B19","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/j.1600-6143.2011.03976.x","article-title":"Summary of the US FDA approval of belatacept","volume":"12","author":"Archdeacon","year":"2012","journal-title":"Am J Transplant"},{"key":"B20","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2147\/BTT.S27565","article-title":"Introduction to the use of belatacept: a fusion protein for the prevention of posttransplant kidney rejection","volume":"6","author":"Ippoliti","year":"2012","journal-title":"Biol Targets Ther"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1111\/j.1600-6143.2008.02377.x","article-title":"The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation","volume":"8","author":"Bluestone","year":"2008","journal-title":"Am J Transplant"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1097\/TP.0b013e3181fe1377","article-title":"Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade","volume":"90","author":"Posselt","year":"2010","journal-title":"Transplantation"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1097\/TP.0000000000004469","article-title":"CD40-CD40l blockade: update on novel investigational therapeutics for transplantation","volume":"107","author":"Singh","year":"2023","journal-title":"Transplantation"},{"key":"B24","doi-asserted-by":"publisher","first-page":"eadf6376","DOI":"10.1126\/scitranslmed.adf6376","article-title":"The anti-CD40l monoclonal antibody AT-1501 promotes islet and kidney allograft survival and function in nonhuman primates","volume":"15","author":"Anwar","year":"2023","journal-title":"Sci Transl Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S2213-8587(22)00114-0","article-title":"Pancreatic islet transplantation in type 1 diabetes: 20-year experience from a single-centre cohort in Canada","volume":"10","author":"Marfil-Garza","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/ajt.12558","article-title":"Evidence for instant blood-mediated inflammatory reaction in clinical autologous islet transplantation","volume":"14","author":"Naziruddin","year":"2014","journal-title":"Am J Transplant"},{"key":"B27","doi-asserted-by":"publisher","first-page":"66","DOI":"10.2337\/diabetes.51.1.66","article-title":"\u03b2-cell death and mass in syngeneically transplanted islets exposed to short- and long-term hyperglycemia","volume":"51","author":"Biarn\u00e9s","year":"2002","journal-title":"Diabetes"},{"key":"B28","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/S0006-291X(03)01392-5","article-title":"Inflammatory mediators expressed in human islets of Langerhans: implications for islet transplantation","volume":"308","author":"Johansson","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"B29","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/tri.12919","article-title":"Intraportal islet transplantation: the impact of the liver microenvironment","volume":"30","author":"Delaune","year":"2017","journal-title":"Transpl Int"},{"key":"B30","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1001\/jama.293.7.830","article-title":"Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes","volume":"293","author":"Hering","year":"2005","journal-title":"JAMA"},{"key":"B31","article-title":"Mycophenolate mofetil","year":""},{"key":"B32","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1046\/j.1600-6143.2003.00351.x","article-title":"Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody","volume":"4","author":"Hering","year":"2004","journal-title":"Am J Transplant"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.3727\/096368910X564058","article-title":"Improving efficacy of clinical islet transplantation with iodixanol-based islet purification, thymoglobulin induction, and blockage of IL-1\u03b2 and TNF-\u03b1","volume":"20","author":"Matsumoto","year":"2011","journal-title":"Cell Transplant"},{"key":"B34","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/j.1600-6143.2011.03796.x","article-title":"Anakinra potentiates the protective effects of etanercept in transplantation of marginal mass human islets in immunodeficient mice","volume":"12","author":"McCall","year":"2012","journal-title":"Am J Transplant"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1007\/s001250051544","article-title":"TNFalpha and IFNgamma potentiate IL-1beta induced mitogen activated protein kinase activity in rat pancreatic islets of Langerhans","volume":"43","author":"Andersen","year":"2000","journal-title":"Diabetologia"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1002\/art.20221","article-title":"Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate","volume":"50","author":"Genovese","year":"2004","journal-title":"Arthritis Rheum"},{"key":"B37","article-title":"Archived\u2014Important Safety Information: Use of Kineret (Anakinra) in Combination with Etanercept\u2014Amgen Canada\u2014For the Public","year":"2002"},{"key":"B38","article-title":"RAPAMUNE (sirolimus) [Package Insert]","year":"2017"},{"key":"B39","article-title":"PROGRAF (tacrolimus) [Package insert]","year":"2020"},{"key":"B40","article-title":"ZINBRYTA (daclizumab) [Package Insert]","year":"2017"},{"key":"B41","article-title":"THYMOGLOBULIN (anti-thymocyte globulin [rabbit]) [Package Insert]","year":"2017"},{"key":"B42","article-title":"Solu-Medrol(methylprednisolone sodium succinate) [Package Insert]","year":"2011"},{"key":"B43","article-title":"CellCept (mycophenolate mofetil) [Package Insert]","year":"2022"},{"key":"B44","article-title":"KINERET (anakinra) [Package Insert]","year":"2012"},{"key":"B45","article-title":"ENBREL (etanercept) [Package Insert]","year":"2022"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1038\/nbt1259","article-title":"Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells","volume":"24","author":"D'Amour","year":"2006","journal-title":"Nat Biotechnol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nbt1393","article-title":"Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo","volume":"26","author":"Kroon","year":"2008","journal-title":"Nat Biotechnol"},{"key":"B48","article-title":"A Prospective, Multicenter, Open-Label, First-in-Human Phase 1\/2 Study With Two Cohorts to Evaluate the Safety, Tolerability, and Efficacy of Various Doses of VC-01\u2122 Combination Product in Subjects With Type 1 Diabetes Mellitus","year":""},{"key":"B49","doi-asserted-by":"publisher","first-page":"e158305","DOI":"10.1172\/JCI158305","article-title":"Reversing type 1 diabetes with stem cell\u2013derived islets: a step closer to the dream?","volume":"132","author":"Butler","year":"2022","journal-title":"J Clin Invest"},{"key":"B50","article-title":"Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1\/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes | Vertex Pharmaceuticals","year":"2021"},{"key":"B51","article-title":"Vertex Presents Positive VX-880 Results From Ongoing Phase 1\/2 Study in Type 1 Diabetes at the American Diabetes Association 83rd Scientific Sessions | Vertex Pharmaceuticals","year":"2023"},{"key":"B52","article-title":"Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes | Vertex Pharmaceuticals","year":"2023"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2100965","DOI":"10.1002\/adhm.202100965","article-title":"Advances in encapsulation and delivery strategies for islet transplantation","volume":"10","author":"Wu","year":"2021","journal-title":"Adv Healthc Mater"},{"key":"B54","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.cell.2014.09.040","article-title":"Generation of functional human pancreatic \u03b2 cells in vitro","volume":"159","author":"Pagliuca","year":"2014","journal-title":"Cell"},{"key":"B55","doi-asserted-by":"publisher","first-page":"11463","DOI":"10.1038\/ncomms11463","article-title":"Generation of stem cell-derived \u03b2-cells from patients with type 1 diabetes","volume":"7","author":"Millman","year":"2016","journal-title":"Nat Commun"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/nbt.3033","article-title":"Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells","volume":"32","author":"Rezania","year":"2014","journal-title":"Nat Biotechnol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"869514","DOI":"10.3389\/fimmu.2022.869514","article-title":"Engineering islets from stem cells: the optimal solution for the treatment of diabetes?","volume":"13","author":"Du","year":"2022","journal-title":"Front Immunol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.2337\/db16-1406","article-title":"Autologous pluripotent stem cell\u2013derived \u03b2-like cells for diabetes cellular therapy","volume":"66","author":"Millman","year":"2017","journal-title":"Diabetes"},{"key":"B59","doi-asserted-by":"publisher","first-page":"716625","DOI":"10.3389\/fendo.2021.716625","article-title":"Immune protection of stem cell-derived islet cell therapy for treating diabetes","volume":"12","author":"Tahbaz","year":"2021","journal-title":"Front Endocrinol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"e941918-1","DOI":"10.12659\/MSM.941918","article-title":"Editorial: first regulatory approval for allogeneic pancreatic islet Beta cell infusion for adult patients with type 1 diabetes Mellitus","volume":"29","author":"Parums","year":"2023","journal-title":"Med Sci Monit"},{"key":"B61","article-title":"New therapy from UI Health offers FDA-approved treatment option for brittle Type 1 diabetes | UIC today","year":"2024"},{"key":"B62","article-title":"FDA (2023). FDA Approves First Cellular Therapy to Treat Patients with Type 1 Diabetes","year":""},{"key":"B63","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"B64","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.3390\/pharmaceutics14122728","article-title":"PLGA-based nanomedicine: history of advancement and development in clinical applications of multiple diseases","volume":"14","author":"Alsaab","year":"2022","journal-title":"Pharmaceutics"},{"key":"B65","doi-asserted-by":"publisher","first-page":"653088","DOI":"10.3389\/fimmu.2021.653088","article-title":"Immunosuppressive PLGA TGF-\u03b21 microparticles induce polyclonal and antigen-specific regulatory T cells for local immunomodulation of allogeneic islet transplants","volume":"12","author":"Li","year":"2021","journal-title":"Front Immunol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/s41467-023-36225-5","article-title":"Engineering the lymph node environment promotes antigen-specific efficacy in type 1 diabetes and islet transplantation","volume":"14","author":"Gammon","year":"2023","journal-title":"Nat Commun"},{"key":"B67","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1111\/ajt.15662","article-title":"Co-localized immune protection using dexamethasone-eluting micelles in a murine islet allograft model","volume":"20","author":"Kuppan","year":"2020","journal-title":"Am J Transplant"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1080\/10717544.2017.1377317","article-title":"Single synchronous delivery of FK506-loaded polymeric microspheres with pancreatic islets for the successful treatment of streptozocin-induced diabetes in mice","volume":"24","author":"Pathak","year":"2017","journal-title":"Drug Deliv"},{"key":"B69","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/s41563-018-0099-0","article-title":"Local immunomodulation with fas ligand-engineered biomaterials achieves allogeneic islet graft acceptance","volume":"17","author":"Headen","year":"2018","journal-title":"Nat Mater"},{"key":"B70","doi-asserted-by":"publisher","first-page":"eaba5573","DOI":"10.1126\/sciadv.aba5573","article-title":"Immunotherapy via PD-L1\u2013presenting biomaterials leads to long-term islet graft survival","volume":"6","author":"Coronel","year":"2020","journal-title":"Sci Adv"},{"key":"B71","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41565-021-01048-2","article-title":"Subcutaneous nanotherapy repurposes the immunosuppressive mechanism of rapamycin to enhance allogeneic islet graft viability","volume":"17","author":"Burke","year":"2022","journal-title":"Nat Nanotechnol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1007\/s11095-014-1340-4","article-title":"Local co-delivery of pancreatic islets and liposomal clodronate using injectable hydrogel to prevent acute immune reactions in a type 1 diabetes","volume":"31","author":"Haque","year":"2014","journal-title":"Pharm Res"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.regen.2018.01.003","article-title":"Evaluation of biomaterial scaffold delivery of IL-33 as a localized immunomodulatory agent to support cell transplantation in adipose tissue","volume":"1","author":"Liu","year":"2018","journal-title":"J Immunol Regen Med"},{"key":"B74","doi-asserted-by":"publisher","first-page":"3660","DOI":"10.2337\/db16-0320","article-title":"Biopatterned CTLA4\/Fc matrices facilitate local immunomodulation, engraftment, and glucose homeostasis after pancreatic islet transplantation","volume":"65","author":"Zhang","year":"2016","journal-title":"Diabetes"},{"key":"B75","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.1021\/acsbiomaterials.3c00329","article-title":"Improvement of islet engrafts via treg induction using immunomodulating polymeric tolerogenic microparticles","volume":"9","author":"Neshat","year":"2023","journal-title":"ACS Biomater Sci Eng"},{"key":"B76","doi-asserted-by":"publisher","first-page":"eabm9881","DOI":"10.1126\/sciadv.abm9881","article-title":"Fasl microgels induce immune acceptance of islet allografts in nonhuman primates","volume":"8","author":"Lei","year":"2022","journal-title":"Sci Adv"},{"key":"B77","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.biomaterials.2018.11.015","article-title":"Localized immune tolerance from FasL-functionalized PLG scaffolds","volume":"192","author":"Skoumal","year":"2019","journal-title":"Biomaterials"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1002\/jbm.a.37429","article-title":"A hydrogel platform for co-delivery of immunomodulatory proteins for pancreatic islet allografts","volume":"110","author":"Medina","year":"2022","journal-title":"J Biomed Mater Res A"},{"key":"B79","doi-asserted-by":"publisher","first-page":"5176","DOI":"10.1038\/s41467-024-49135-x","article-title":"Immuno-protective vesicle-crosslinked hydrogel for allogenic transplantation","volume":"15","author":"Wang","year":"2024","journal-title":"Nat Commun"},{"key":"B80","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.1002\/adma.201200446","article-title":"Engineering nano- and micro-particles to tune immunity","volume":"24","author":"Moon","year":"2012","journal-title":"Adv Mater Deerfield Beach Fla"},{"key":"B81","doi-asserted-by":"publisher","first-page":"6530","DOI":"10.1002\/adma.201402105","article-title":"Hydrogels and scaffolds for immunomodulation","volume":"26","author":"Singh","year":"2014","journal-title":"Adv Mater Deerfield Beach Fla"},{"key":"B82","doi-asserted-by":"publisher","first-page":"eabj1577","DOI":"10.1126\/sciadv.abj1577","article-title":"Nanocapsules modify membrane interaction of polymyxin B to enable safe systemic therapy of Gram-negative sepsis","volume":"7","author":"Yuk","year":"2021","journal-title":"Sci Adv"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.2337\/db05-1220","article-title":"Dexamethasone induces cell death in insulin-secreting cells, an effect reversed by exendin-4","volume":"55","author":"Ranta","year":"2006","journal-title":"Diabetes"},{"key":"B84","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.biomaterials.2016.11.004","article-title":"Local release of dexamethasone from macroporous scaffolds accelerates islet transplant engraftment by promotion of anti-inflammatory M2 macrophages","volume":"114","author":"Jiang","year":"2017","journal-title":"Biomaterials"},{"key":"B85","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1586\/eci.09.64","article-title":"Role of T cells in graft rejection and transplantation tolerance","volume":"6","author":"Issa","year":"2010","journal-title":"Expert Rev Clin Immunol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"4743","DOI":"10.1182\/blood-2004-10-3932","article-title":"Rapamycin selectively expands CD4+ CD25+ FoxP3+ regulatory T cells","volume":"105","author":"Battaglia","year":"2005","journal-title":"Blood"},{"key":"B87","doi-asserted-by":"publisher","first-page":"v","DOI":"10.1007\/978-3-540-71029-5","article-title":"Handbook of experimental pharmacology: preface","volume":"188","author":"Lombardi","year":"2009","journal-title":"Handb Exp Pharmacol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"652","DOI":"10.3390\/pharmaceutics16050652","article-title":"Drug integrating amphiphilic nano-assemblies: 2. Spatiotemporal distribution within inflammation sites","volume":"16","author":"De Toni","year":"2024","journal-title":"Pharmaceutics"},{"key":"B89","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/00007691-199512000-00007","article-title":"Mode of action of tacrolimus (FK506): molecular and cellular mechanisms","volume":"17","author":"Thomson","year":"1995","journal-title":"Ther Drug Monit"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/s42255-020-0269-7","article-title":"Islet transplantation in the subcutaneous space achieves long-term euglycaemia in preclinical models of type 1 diabetes","volume":"2","author":"Yu","year":"2020","journal-title":"Nat Metab"},{"key":"B91","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/nbt.3211","article-title":"A prevascularized subcutaneous device-less site for islet and cellular transplantation","volume":"33","author":"Pepper","year":"2015","journal-title":"Nat Biotechnol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1007\/s00125-011-2243-0","article-title":"Advancing islet transplantation: from engraftment to the immune response","volume":"54","author":"Gibly","year":"2011","journal-title":"Diabetologia"},{"key":"B93","first-page":"391","article-title":"Chapter 16\u2014neural ECM mimetics","volume-title":"Progress in Brain Research","author":"Estrada","year":"2014"},{"key":"B94","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nri.2016.95","article-title":"Interleukin-33 in health and disease","volume":"16","author":"Liew","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1097\/TP.0b013e3181d720af","article-title":"IL-33 prolongs murine cardiac allograft survival through induction of TH2-type immune deviation","volume":"89","author":"Yin","year":"2010","journal-title":"Transplantation"},{"key":"B96","doi-asserted-by":"publisher","first-page":"4598","DOI":"10.4049\/jimmunol.1100519","article-title":"IL-33 expands suppressive CD11b+ Gr-1int and regulatory T cells, including ST2L+ Foxp3+ cells, and mediates regulatory T cell-dependent promotion of cardiac allograft survival","volume":"187","author":"Turnquist","year":"2011","journal-title":"J Immunol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1111\/j.1600-6143.2012.04184.x","article-title":"CTLA4-Ig restores rejection of MHC class-II mismatched allografts by disabling IL-2-expanded regulatory T cells","volume":"12","author":"Charbonnier","year":"2012","journal-title":"Am J Transplant"},{"key":"B98","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.2337\/diabetes.53.11.2797","article-title":"Fas deficiency prevents type 1 diabetes by inducing hyporesponsiveness in islet \u03b2-cell\u2212reactive T-cells","volume":"53","author":"Vence","year":"2004","journal-title":"Diabetes"},{"key":"B99","doi-asserted-by":"publisher","first-page":"529","DOI":"10.2337\/db13-1737","article-title":"PD-L1\u2013driven tolerance protects neurogenin3-induced islet neogenesis to reverse established type 1 diabetes in NOD mice","volume":"64","author":"Li","year":"2015","journal-title":"Diabetes"},{"key":"B100","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/373444a0","article-title":"Fas(CD95)\/FasL interactions required for programmed cell death after T-cell activation","volume":"373","author":"Ju","year":"1995","journal-title":"Nature"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1080\/21645515.2019.1571892","article-title":"PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations","volume":"15","author":"Jiang","year":"2019","journal-title":"Hum Vaccines Immunother"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.4049\/jimmunol.1100056","article-title":"The novel costimulatory programmed death ligand 1\/B7.1 pathway is functional in inhibiting alloimmune responses in vivo","volume":"187","author":"Yang","year":"2011","journal-title":"J Immunol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"622810","DOI":"10.3389\/fimmu.2020.622810","article-title":"Treg therapies revisited: tolerance beyond deletion","volume":"11","author":"Pilat","year":"2021","journal-title":"Front Immunol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1038\/353858a0","article-title":"lnterleukin-2 programs mouse \u03b1\u03b2 T lymphocytes for apoptosis","volume":"353","author":"Lenardo","year":"1991","journal-title":"Nature"},{"key":"B105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-021-00710-4","article-title":"The secretion profile of mesenchymal stem cells and potential applications in treating human diseases","volume":"7","author":"Han","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B106","doi-asserted-by":"publisher","first-page":"eabn0071","DOI":"10.1126\/sciadv.abn0071","article-title":"Engineered immunomodulatory accessory cells improve experimental allogeneic islet transplantation without immunosuppression","volume":"8","author":"Wang","year":"2022","journal-title":"Sci Adv"},{"key":"B107","doi-asserted-by":"publisher","first-page":"5901","DOI":"10.4049\/jimmunol.1003266","article-title":"Pancreatic islets engineered with SA-FasL protein establish robust localized tolerance by inducing regulatory T cells in mice","volume":"187","author":"Yolcu","year":"2011","journal-title":"J Immunol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.4049\/jimmunol.2000055","article-title":"Localized immunomodulation with PD-L1 results in sustained survival and function of allogeneic islets without chronic immunosuppression","volume":"204","author":"Batra","year":"2020","journal-title":"J Immunol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/01.TP.0000438198.76531.03","article-title":"Transplantation of co-aggregates of sertoli cells and islet cells into liver without immunosuppression","volume":"97","author":"Takemoto","year":"2014","journal-title":"Transplantation"},{"key":"B110","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1097\/TP.0000000000000579","article-title":"Coaggregates of regulatory T cells and islet cells allow long-term graft survival in liver without immunosuppression","volume":"99","author":"Takemoto","year":"2015","journal-title":"Transplantation"},{"key":"B111","doi-asserted-by":"publisher","first-page":"4107943","DOI":"10.1155\/2017\/4107943","article-title":"Cotransplantation of mesenchymal stem cells and immature dendritic cells potentiates the blood glucose control of islet allografts","volume":"2017","author":"Long","year":"2017","journal-title":"BioMed Res Int"},{"key":"B112","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1111\/ajt.15347","article-title":"Cotransplantation of preactivated mesenchymal stem cells improves intraportal engraftment of islets by inhibiting liver natural killer cells in mice","volume":"19","author":"Ishida","year":"2019","journal-title":"Am J Transplant"},{"key":"B113","doi-asserted-by":"publisher","first-page":"3524","DOI":"10.1111\/ajt.16693","article-title":"Extended survival versus accelerated rejection of nonhuman primate islet allografts: effect of mesenchymal stem cell source and timing","volume":"21","author":"Kenyon","year":"2021","journal-title":"Am J Transplant"},{"key":"B114","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/cmi.2013.16","article-title":"Apoptotic cell administration enhances pancreatic islet engraftment by induction of regulatory T cells and tolerogenic dendritic cells","volume":"10","author":"Wu","year":"2013","journal-title":"Cell Mol Immunol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.diabet.2012.08.008","article-title":"Intravenous infusion of donor apoptotic leukocytes before transplantation delays allogeneic islet graft rejection through regulatory T cells","volume":"38","author":"Mougel","year":"2012","journal-title":"Diabetes Metab"},{"key":"B116","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1111\/ajt.13329","article-title":"Pilot study evaluating regulatory T cell\u2013promoting immunosuppression and nonimmunogenic donor antigen delivery in a nonhuman primate islet allotransplantation model","volume":"15","author":"Lei","year":"2015","journal-title":"Am J Transplant"},{"key":"B117","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1038\/s41467-019-11338-y","article-title":"Long-term tolerance of islet allografts in nonhuman primates induced by apoptotic donor leukocytes","volume":"10","author":"Singh","year":"2019","journal-title":"Nat Commun"},{"key":"B118","doi-asserted-by":"publisher","first-page":"3601","DOI":"10.4049\/jimmunol.162.6.3601","article-title":"Soluble fas ligand is chemotactic for human neutrophilic polymorphonuclear Leukocytes1","volume":"162","author":"Ottonello","year":"1999","journal-title":"J Immunol"},{"key":"B119","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.1073\/pnas.0915174107","article-title":"PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors","volume":"107","author":"Curran","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B120","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/j.1600-065X.2008.00662.x","article-title":"Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways","volume":"224","author":"Fife","year":"2008","journal-title":"Immunol Rev"},{"key":"B121","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nm.3028","article-title":"The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine","volume":"19","author":"Bianco","year":"2013","journal-title":"Nat Med"},{"key":"B122","doi-asserted-by":"publisher","first-page":"e47559","DOI":"10.1371\/journal.pone.0047559","article-title":"Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials","volume":"7","author":"Lalu","year":"2012","journal-title":"PLoS One"},{"key":"B123","doi-asserted-by":"publisher","first-page":"2003708","DOI":"10.1002\/advs.202003708","article-title":"Local immunomodulatory strategies to prevent allo-rejection in transplantation of insulin-producing cells","volume":"8","author":"Wang","year":"2021","journal-title":"Adv Sci"},{"key":"B124","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1095\/biolreprod60.6.1304","article-title":"Expression and action of transforming growth factor Beta (TGF\u03b21, TGF\u03b22, and TGF\u03b23) during embryonic rat testis Development1","volume":"60","author":"Cupp","year":"1999","journal-title":"Biol Reprod"},{"key":"B125","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2337\/diab.46.2.317","article-title":"Cotransplantation of allogeneic islets with allogeneic testicular cell aggregates allows long-term graft survival without systemic immunosuppression","volume":"46","author":"Korbutt","year":"1997","journal-title":"Diabetes"},{"key":"B126","doi-asserted-by":"publisher","first-page":"25784","DOI":"10.1073\/pnas.1910701116","article-title":"Treg-inducing microparticles promote donor-specific tolerance in experimental vascularized composite allotransplantation","volume":"116","author":"Fisher","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B127","doi-asserted-by":"publisher","first-page":"e69640","DOI":"10.1371\/journal.pone.0069640","article-title":"Alternative immunomodulatory strategies for xenotransplantation: CD80\/CD86-CTLA4 pathway-modified immature dendritic cells promote xenograft survival","volume":"8","author":"Tian","year":"2013","journal-title":"PLoS One"},{"key":"B128","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/01.tp.0000244572.24780.54","article-title":"Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle","volume":"83","author":"Ramasamy","year":"2007","journal-title":"Transplantation"},{"key":"B129","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1634\/stemcells.2004-0359","article-title":"Interactions between human mesenchymal stem cells and natural killer cells","volume":"24","author":"Sotiropoulou","year":"2006","journal-title":"Stem Cells"},{"key":"B130","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1016\/j.transproceed.2009.06.119","article-title":"Mesenchymal stem cells require a sufficient, ongoing immune response to exert their immunosuppressive function","volume":"41","author":"Renner","year":"2009","journal-title":"Transplant Proc"},{"key":"B131","doi-asserted-by":"publisher","first-page":"626840","DOI":"10.3389\/fimmu.2021.626840","article-title":"Apoptotic donor cells in transplantation","volume":"12","author":"Husain","year":"2021","journal-title":"Front Immunol"},{"key":"B132","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3389\/fimmu.2020.00553","article-title":"Phagocytosis of apoptotic cells in resolution of inflammation","volume":"11","author":"Kourtzelis","year":"2020","journal-title":"Front Immunol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3389\/fmed.2018.00202","article-title":"The future of islet transplantation is now","volume":"5","author":"Bottino","year":"2018","journal-title":"Front Med"},{"key":"B134","article-title":"Gene and Cell Therapies: Navigating the Challenges Around Rising Costs in Medical Insurance","year":"2023"},{"key":"B135","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1111\/ajt.16397","article-title":"The demise of islet allotransplantation in the United States: a call for an urgent regulatory update","volume":"21","author":"Witkowski","year":"2021","journal-title":"Am J Transplant"},{"key":"B136","article-title":"ADA Meeting News","year":"2021"},{"key":"B137","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.stem.2018.05.016","article-title":"Stem cell therapies for treating diabetes: progress and remaining challenges","volume":"22","author":"Sneddon","year":"2018","journal-title":"Cell Stem Cell"},{"key":"B138","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41578-019-0112-5","article-title":"Engineering immunomodulatory biomaterials for type 1 diabetes","volume":"4","author":"Stabler","year":"2019","journal-title":"Nat Rev Mater"},{"key":"B139","doi-asserted-by":"publisher","first-page":"989815","DOI":"10.3389\/fendo.2022.989815","article-title":"Human stem cell derived beta-like cells engineered to present PD-L1 improve transplant survival in NOD mice carrying human HLA class I","volume":"13","author":"Santini-Gonz\u00e1lez","year":"2022","journal-title":"Front Endocrinol"},{"key":"B140","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s13287-024-03810-4","article-title":"Hypoimmunogenic human iPSCs expressing HLA-G, PD-L1, and PD-L2 evade innate and adaptive immunity","volume":"15","author":"Tsuneyoshi","year":"2024","journal-title":"Stem Cell Res Ther"},{"key":"B141","article-title":"FDA, (2024). FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease","year":""},{"key":"B142","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nrd.2016.232","article-title":"Advances in islet encapsulation technologies","volume":"16","author":"Desai","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"B143","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.actbio.2019.05.051","article-title":"Engineering the vasculature for islet transplantation","volume":"95","author":"Bowers","year":"2019","journal-title":"Acta Biomater"},{"key":"B144","doi-asserted-by":"publisher","first-page":"115179","DOI":"10.1016\/j.addr.2024.115179","article-title":"Immunoprotection of cellular transplants for autoimmune type 1 diabetes through local drug delivery","volume":"206","author":"Lansberry","year":"2024","journal-title":"Adv Drug Deliv Rev"},{"key":"B145","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.scr.2009.02.002","article-title":"Teratoma formation by human embryonic stem cells: evaluation of essential parameters for future safety studies","volume":"2","author":"Hentze","year":"2009","journal-title":"Stem Cell Res"},{"key":"B146","doi-asserted-by":"publisher","first-page":"732431","DOI":"10.3389\/fendo.2021.732431","article-title":"Advances in pancreatic islet transplantation sites for the treatment of diabetes","volume":"12","author":"Cayabyab","year":"2021","journal-title":"Front Endocrinol"},{"key":"B147","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1080\/19382014.2021.1954459","article-title":"An overview of current advancements in pancreatic islet transplantation into the omentum","volume":"13","author":"Damyar","year":"2021","journal-title":"Islets"},{"key":"B148","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.4049\/jimmunol.153.3.1080","article-title":"Immunoreactive vasoactive intestinal peptide contributes to the immunosuppressive activity of normal aqueous humor","volume":"153","author":"Taylor","year":"1994","journal-title":"J Immunol"},{"key":"B149","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1076\/ceyr.16.9.900.5043","article-title":"Aqueous humor induces transforming growth factor-\u00df (TGF-\u00df)-producing regulatory T-cells","volume":"16","author":"Taylor","year":"1997","journal-title":"Curr Eye Res"},{"key":"B150","doi-asserted-by":"publisher","first-page":"17612","DOI":"10.1073\/pnas.1414053111","article-title":"Young capillary vessels rejuvenate aged pancreatic islets","volume":"111","author":"Alma\u00e7a","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B151","doi-asserted-by":"publisher","first-page":"6646","DOI":"10.1038\/s41598-017-07015-z","article-title":"Biochemical profiling of diabetes disease progression by multivariate vibrational microspectroscopy of the pancreas","volume":"7","author":"Nord","year":"2017","journal-title":"Sci Rep"},{"key":"B152","doi-asserted-by":"publisher","first-page":"12623","DOI":"10.1038\/ncomms12623","article-title":"Graft-infiltrating host dendritic cells play a key role in organ transplant rejection","volume":"7","author":"Zhuang","year":"2016","journal-title":"Nat Commun"},{"key":"B153","doi-asserted-by":"publisher","first-page":"306","DOI":"10.2337\/diabetes.54.2.306","article-title":"Antigen-specific FoxP3-transduced T-cells can control established type 1 diabetes","volume":"54","author":"Jaeckel","year":"2005","journal-title":"Diabetes"},{"key":"B154","doi-asserted-by":"publisher","first-page":"2200135","DOI":"10.1002\/anbr.202200135","article-title":"Delivery route considerations for designing antigen-specific biomaterial strategies to combat autoimmunity","volume":"3","author":"Ackun-Farmmer","year":"2023","journal-title":"Adv Nanobiomed Res"},{"key":"B155","doi-asserted-by":"publisher","first-page":"0963689720913876","DOI":"10.1177\/0963689720913876","article-title":"Donor-specific regulatory T cell-mediated immune tolerance in an intrahepatic murine allogeneic islet transplantation model with short-term anti-CD154 mAb single treatment","volume":"29","author":"Lee","year":"2020","journal-title":"Cell Transplant"},{"key":"B156","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s11892-015-0659-5","article-title":"Targeting memory T cells in type 1 diabetes","volume":"15","author":"Ehlers","year":"2015","journal-title":"Curr Diab Rep"},{"key":"B157","doi-asserted-by":"publisher","first-page":"79","DOI":"10.4161\/isl.24698","article-title":"Murine animal models for preclinical islet transplantation","volume":"5","author":"Cantarelli","year":"2013","journal-title":"Islets"},{"key":"B158","article-title":"Beta-cell function and human islet transplantation: can we improve? (2021)","author":"Chen","year":""},{"key":"B159","doi-asserted-by":"publisher","first-page":"216","DOI":"10.4049\/jimmunol.2300527","article-title":"Rational engineering of islet tolerance via biomaterial-mediated immune modulation","volume":"212","author":"Klug","year":"2024","journal-title":"J Immunol"},{"key":"B160","doi-asserted-by":"publisher","first-page":"923241","DOI":"10.3389\/fimmu.2022.923241","article-title":"Immune-protective formulations and process strategies for improved survival and function of transplanted islets","volume":"13","author":"Shi","year":"2022","journal-title":"Front Immunol"}],"container-title":["Frontiers in Transplantation"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frtra.2025.1514956\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T07:47:02Z","timestamp":1742456822000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frtra.2025.1514956\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":160,"alternative-id":["10.3389\/frtra.2025.1514956"],"URL":"https:\/\/doi.org\/10.3389\/frtra.2025.1514956","relation":{},"ISSN":["2813-2440"],"issn-type":[{"value":"2813-2440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,20]]},"article-number":"1514956"}}